Explore the vast range of titles available.

Introduction/BackgroundExposure to platinum and taxane-based chemotherapy is associated with the risk of developing hypersensitivity reactions (HSRs), which may necessitate the use of less effective treatments to avoid anaphylaxis. Desensitisation to platinum and taxane HSRs can be used to complete chemotherapy according to the standard regimen; therefore, this study investigated the current management of HSRs to platinum and/or taxane chemotherapy in patients with gynaecological cancers.MethodologyWe conducted a cross-sectional survey among gynaecological and medical oncologist consisting of 33 questions. SurveyMonkey software was used to create and distribute the questionnaire. The survey was posted online on the ENYGO and Oncoalert social media channels and data were collected from 1) members of ENYGO and ESGO and 2)ESGO/ENYGO followers.ResultsA total of 144 respondents completed the survey and 133 respondents were included in the final analysis. The gender of the participants was balanced with 54.9% female and 45.1% male with an average age of 38 years. The majority of participants were gynaecological oncologists (43.6%) and medical oncologists (33.8%) working mainly in a university hospital (57.1%) and 77.4%(n=103) were involved in chemotherapy treatment. Of these, 79 participants administered platinum and 67 participants taxane-based chemotherapy. The majority of participants experienced more than 5 HSRs to platinum and taxane per year (73.4% and 73.1%, respectively). Pre-medication with antihistamines/steroids and a new attempt at standard infusion with platinum or taxane chemotherapy were used in 84.8% and 92.5% of Grade 1–2 HSRs to platinum and taxane, respectively. In contrast, tolerance induction was used in 49.4% and 41.8% of Grade 3–4 HSRs to platinum and taxane, respectively. Tolerance induction was mainly performed by medical oncologists,allergists and gynaecological oncologists.ConclusionThe majority of participants strongly emphasised the need to standardise the management of platinum and taxane HSR in gynaecological cancer and to develop international guidelines, regardless of their involvement in chemotherapy treatment.DisclosuresAll of the authors have no conflicts of interest to disclose.

Platinum and taxane chemotherapy is associated with the risk of hypersensitivity reactions (HSRs), which may require switching to less effective treatments. Desensitization to platinum and taxane HSRs can be used to complete chemotherapy according to the standard regimen. Therefore, we aimed to investigate the current management of HSRs to platinum and/or taxane chemotherapy in patients with gynecologic cancers. We conducted an online cross-sectional survey among gynecological and medical oncologists consisting of 33 questions. A total of 144 respondents completed the survey, and 133 respondents were included in the final analysis. Most participants were gynecologic oncologists (43.6%) and medical oncologists (33.8%), and 77.4% (n = 103) were involved in chemotherapy treatment. More than 73% of participants experienced >5 HSRs to platinum and taxane per year. Premedication and a new attempt with platinum or taxane chemotherapy were used in 84.8% and 92.5% of Grade 1–2 HSRs to platinum and taxane, respectively. In contrast, desensitization was used in 49.4% and 41.8% of Grade 3–4 HSRs to platinum and taxane, respectively. Most participants strongly emphasized the need to standardize the management of platinum and taxane HSRs in gynecologic cancer. Our study showed that HSRs in gynecologic cancer are common, but management is variable and the use of desensitization is low. In addition, the need for guidance on the management of platinum- and taxane-induced HSRs in gynecologic cancer was highlighted.